At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 206 enrolled
Drug / intervention
PF-06291874 +1 moredrug
Likely dose
PF-06291874 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
In Brief
A Phase 2 clinical trial evaluating PF-06291874 and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 206 participants across 38 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether PF-06291874 is effective in the treatment T2DM
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartOct 2015
Primary CompletionAug 2016
TodayJul 2026
First PostedSep 18, 2015
Enrollment StartOct 1, 2015
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.8 years ago
Interventions
PF-06291874drug
study drug to be given as an oral tablet at 30, 60 or 100 mg
Placebodrug
oral tablet